Table 3. Univariate and multivariate analyses of OS and PFS in NSCLC patients.

Parameter	OS								PFS
	Univariate analysis					Multivariate analysis			Univariate analysis					Multivariate analysis
		N	HR	95%CI	P-value	HR	95%CI	P-value		N	HR	95%CI	P-value	HR	95%CI	P-value
Age
≤50y	1	45							1	45
>50y		125	2.552	1.082-6.019	0.032	2.602	1.078-6.279	0.033		125	0.77	0.483-1.229	0.274	0.69	0.428-1.112	0.128
Gender
female	1	77							1	77
male		93	1.737	0.963-3.131	0.066	1.346	0.649-2.795	0.425		93	1.779	1.147-2.760	0.010	1.245	0.704-2.200	0.451
Smoking
no	1	113							1	113
yes		57	1.718	0.921-3.207	0.089	1.218	0.552-2.684	0.626		57	1.832	1.179-2.846	0.007	1.364	0.761-2.445	0.297
Pathology
ADC	1	145							1	145
non-ADC		25	1.349	0.604-3.017	0.465	1.548	0.680-3.520	0.298		25	1.59	0.894-2.826	0.114	1.396	0.776-2.508	0.265
Stage
IIIB	1	9							1	9
IV		161	1.199	0.370-3.890	0.762	1.030	0.291-3.650	0.963		161	1.627	0.594-4.455	0.344	0.822	0.284-2.382	0.719
EGFR
wild type	1	71							1	71
mutation		99	0.485	0.271-0.868	0.015	0.499	0.264-0.942	0.032		99	0.365	0.237-0.562	<0.001	0.419	0.262-0.672	<0.001
EGFR-TKI
1st line	1	83							1	83
≥2nd line		87	1.338	0.751-2.384	0.323	1.562	0.839-2.906	0.159		87	1.941	1.257-2.996	0.003	1.756	1.099-2.806	0.019
PD-L1
negative	1	58							1	58
positive		112	1.472	0.776-2.792	0.236	1.901	0.953-3.790	0.068		112	1.003	0.641-1.569	0.990	1.315	0.831-2.080	0.242

Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; 95%CI, 95% confidence intervals; ADC, adenocarcinoma; non-ADC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; PD-L1, programmed cell death-ligand 1.